H1 19: no surprise
H1 19: no surpriseEARNINGS/SALES RELEASES
FACT
Crossject released its H1 19 results. Revenues reached €1,844k (vs €2,840k), operating result €-5,873k (vs €-5,337k), and the net result €4,953k (vs €-4,744k). Net cash at the end of H1 19 was €1.5m (vs €0.8m) and €4.82m at the end of FY18.
ANALYSIS
As always, results as such are not very important since no product has reached the market yet, except for the cash-burn (excluding new financing) which has reached €4.3m, a “decent†number. Turnover reached €0.5m, a direct consequence of the agreement with German Desitin on the licensing, distribution and promotion, until 10 years after commercial launch, of Zeneo Midazolam in Germany (see our paper dated 18 June 2019). The company also indicated that the calendar for product filings is unchanged, with Naloxone, Midazolam and Adrenaline as the first candidates in FY20. On the P&L front, it is worth mentioning that external charges were well under control (-21.7% to €3.2m) due to the decrease in external staffing and a tight control of inventories. As a result, and despite the decrease in total revenues due to a lower production level, the operating result was almost flat year-on-year, “only†down from €-5.3m to €-5.7m. In terms of financing, the group asserts it is expecting an additional €4m cash-inflow in the next 12 months (from the Piave programme, tax credits or Desitin’s milestones) while it is working on other options, with a priority put on non-dilutive ones. The potential signature of new commercial agreements could ease things, but it is of course impossible to bet on it and even harder to guess what the timing of such a prospect could be.
IMPACT
No big change to our numbers and valuation to be expected after this release. The question mark on financing remains, which is no surprise and certainly caps the share price performance before more is known on potential commercial agreements. This does not change our positive view on the group’s progress on its way to reach the market, with a very significant upside potential for the share price once the first launches actually take place.
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.